肝脏特定的电离性脂质纳米颗粒通过有效的RNA干扰来清除"坏胆固醇"
Chuangjia Huang1,2, Yu Zhang3, Jianfen Su1,2
1Department of Cardiology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, People's Republic of China.
International journal of nanomedicine
|December 25, 2023
概括
针对肝脏的新纳米颗粒有效地提供siRNA来降低PCSK9水平. 这种方法显著降低了LDL-C,为动脉样硬化心血管疾病提供了有前途的新疗法.
科学领域:
- 生物技术是生物技术.
- 心血管研究研究心血管研究
- 基因治疗 基因治疗
背景情况:
- 高的LDL-C是动脉样硬化心血管疾病的关键因素.
- PCSK9蛋白调节LDL受体 (LDLR) 和血LDL-C水平.
- 降低PCSK9的表达,可以提高肝脏的LDLRs,降低LDL-C.
研究的目的:
- 开发肝脏特定的纳米颗粒,以提供高效的siRNA输送.
- 针对肝细胞进行PCsk9.9的基因沉默.
- 评估降低LDL-C的治疗潜力.
主要方法:
- 开发用于siRNA输送的肝脏特定的可电离性脂质纳米颗粒 (GLP).
- 纳米粒子具有很高的稳定性和膜活性聚合物,用于有针对性的释放.
- 在体外和体内研究评估基因沉默和LDL-C降低.
主要成果:
- 在实验室中,GLP纳米粒子实现了90%的PCsk9mRNA沉默.
- 在体内研究显示,肝脏LDLR水平增加了3.35倍.
- 血LDL-C在体内减少了35%.
结论:
- GLP纳米颗粒显示出强大的LDL-C降低效应.
- 这项技术为动脉样硬化心血管疾病提供了潜在的治疗策略.
- 针对性地向肝细胞传递siRNA是有效的管理高胆固醇血症.
相关概念视频
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
667
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
667
Small interfering RNAs (siRNA)
3.5K
3.5K


